EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function

Markus Barden iD, Patrick Ronan Elsenbroich iD, Vivian Haas, Moritz Ertelt, Philip Pervan, Lukas Velas, Bence Gergely iD, Árpád Szöőr, Dennis Christoph Harrer, Valerie Bezler, Astrid Holzinger, Rasmus Ulslev Wegener Friis und 5 weitere

Journal for ImmunoTherapy of Cancer · 2024-12 · 12 (12) · e010208

DOI: 10.1136/jitc-2024-010208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 02.12.2024. Verfasst von Markus Barden und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetic Immunotherapy, Leibniz Institute for Immunotherapy, Regensburg, Germany. Hauptthemen laut MEDLINE: T-Lymphocytes, Signal Transduction, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The success of chimeric antigen receptor (CAR) T cell therapy for hematological malignancies has not yet translated into long-term elimination of solid tumors indicating the need for adequately tuning CAR T cell functionality.

Methods

We leveraged a translational pipeline including biophysical characterization and structural prediction of the CAR binding moiety, evaluation of cellular avidity, synapse formation, T cell motility, and functional capacities under repetitive target challenge and in sustained tumor control.

Results

As an example of clinical relevance, we derived a panel of anti-Her2 CARs covering a 4-log affinity range, all expected to target the same Her2 epitope. The same scFv mutations increased both antigen-specific affinity, cellular avidity, and antigen-independent “tonic” signaling; above a minimum threshold, raise in affinity translated into functional avidity in a non-linear fashion. In this case, replacement by amino acids of higher hydrophobicity within the scFv coincidentally augmented affinity, non-specific binding, spontaneous CAR clustering, and tonic signaling, all together relating to T cell functionality in an integrated fashion.

Conclusions

Data emphasize that tonic signaling is not always due to the positive charge but can be driven by hydrophobic interactions of the scFv. CAR binding affinity above the threshold and tonic signaling are required for sustained T cell functionality in antigen rechallenge and long-term tumor control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-LymphocytesSignal TransductionReceptors, Chimeric AntigenHumansAnimalsMiceImmunotherapy, AdoptiveErb-b2 Receptor Tyrosine KinasesCell Line, Tumor

Stichwörter der Autor:innen

Chimeric antigen receptor - CARImmunotherapyT cell

Substanzen

Receptors, Chimeric AntigenErb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Division of Genetic Immunotherapy, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Institute for Drug Discovery, Leipzig University Faculty of Medicine, Leipzig, Germany.
  • Center for Scalable Data Analytics and Artificial Intelligence, ScaDS.AI, Dresden/Leipzig, Germany.
  • Institute of Applied Physics, TU Wien, Vienna, Austria.
  • Department of Biophysics and Cell Biology, University of Debrecen Faculty of Medicine, Debrecen, Hungary.
  • Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark.

ORCID-Profile: Markus Barden, Patrick Ronan Elsenbroich, Bence Gergely, Andreas A Hombach

Zitieren

APA

Barden, M., Elsenbroich, P. R., Haas, V., Ertelt, M., Pervan, P., Velas, L., Gergely, B., Szöőr, Á., Harrer, D. C., Bezler, V., Holzinger, A., Friis, R. U. W., Vereb, G., Schütz, G. J., Schoeder, C. T., Hombach, A. A., & Abken, H. (2024). Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function. Journal for ImmunoTherapy of Cancer, 12(12), e010208. https://doi.org/10.1136/jitc-2024-010208

Vancouver

Barden M, Elsenbroich PR, Haas V, Ertelt M, Pervan P, Velas L, et al. Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function. Journal for ImmunoTherapy of Cancer. 2024;12(12):e010208. doi:10.1136/jitc-2024-010208

BibTeX
@article{Barden2024,
  author = {Barden, Markus and Elsenbroich, Patrick Ronan and Haas, Vivian and Ertelt, Moritz and Pervan, Philip and Velas, Lukas and Gergely, Bence and Szöőr, Árpád and Harrer, Dennis Christoph and Bezler, Valerie and Holzinger, Astrid and Friis, Rasmus Ulslev Wegener and Vereb, Gyorgy and Schütz, Gerhard J and Schoeder, Clara T and Hombach, Andreas A and Abken, Hinrich},
  title = {Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {12},
  pages = {e010208},
  doi = {10.1136/jitc-2024-010208}
}
Kostenlos starten →